In Vitro and Clinical Pharmacokinetic Studies of the Effects of Iron-containing Agents on Vadadustat, an Oral Hypoxia-inducible Factor–Prolyl Hydroxylase Inhibitor-Reference-Cited by-同舟云学术

In Vitro and Clinical Pharmacokinetic Studies of the Effects of Iron-containing Agents on Vadadustat, an Oral Hypoxia-inducible Factor–Prolyl Hydroxylase Inhibitor

Published:2021-08 Issue:8 Volume:43 Page:1408-1418.e5
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Kokado Yoshimasa,Kawai Kouji,Nanjo Takehiro,Kinoshita Shuji,Kondo Kazuoki

Funder

Mitsubishi Tanabe Pharma Corporation

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference33 articles.

1. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease;KDIGO Working Group;Kidney Int Suppl,2013

2. Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis;Koulouridis;Am J Kidney Dis,2013

3. The new FDA labeling for ESA—implications for patients and providers;Manns;Clin J Am Soc Nephrol,2012

4. Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease;McCullough;Am J Nephrol,2013

5. Increased mortality in haemodialysis patients administered high doses of erythropoiesis-stimulating agents: a propensity score-matched analysis;Pérez-García;Nephrol Dial Transplant,2018

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of outcomes on hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) in anaemia associated with chronic kidney disease: network meta-analyses in dialysis and non-dialysis dependent populations;Clinical Kidney Journal;2023-12-07

2. Non-clinical studies indicating lack of interactions between iron/calcium ions and linzagolix, an orally available GnRH antagonist;Xenobiotica;2022-05-04

3. Enhancing fracture repair: cell-based approaches;OTA International: The Open Access Journal of Orthopaedic Trauma;2022-03